Pfizer, Israel strike deal for 8 million doses of potential COVID19 vaccine
In televised remarks, Netanyahu said the agreement marked "a great day for Israel" and added: "The goal is for the vaccine supply to start in January and increase in the months thereafter".
Tel Aviv: Israel signed a deal with Pfizer Inc on Friday to receive 8 million doses of the drugmaker's potential COVID-19 vaccine, Prime Minister Benjamin Netanyahu said, enough to cover close to half of Israel's population.Pfizer and German partner BioNTech SE confirmed a deal was forthcoming in a statement on Thursday but did not disclose financial details. There was no immediate comment...
Tel Aviv: Israel signed a deal with Pfizer Inc on Friday to receive 8 million doses of the drugmaker's potential COVID-19 vaccine, Prime Minister Benjamin Netanyahu said, enough to cover close to half of Israel's population.
Pfizer and German partner BioNTech SE confirmed a deal was forthcoming in a statement on Thursday but did not disclose financial details. There was no immediate comment from the two companies on Friday.
The agreement still requires approval by the U.S. Food and Drug Administration (FDA) and Israel's health ministry, Israeli Health Minister Yuli Edelstein said. Pfizer is expected to apply for approval this month, he added.
Pfizer's potential vaccine is likely to be a two-dose course of treatment, meaning that 8 million doses would cover 4 million of Israel's 9 million population.
In televised remarks, Netanyahu said the agreement marked "a great day for Israel" and added: "The goal is for the vaccine supply to start in January and increase in the months thereafter".
Pfizer on Monday announced that its experimental COVID-19 vaccine was more than 90% effective based on initial trial results, a potential major victory in the war against a virus that has killed more than a million people and battered the world economy.
In addition to its new deal with Pfizer, Israel has an agreement with Moderna Inc for the future purchase of its potential vaccine. Moderna said on Wednesday it had enough data for a first interim analysis of the late-stage trial of its vaccine candidate.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd